Redeye: Annexin Q1 - Positioned for dealmaking
11 juni, 11:12
11 juni, 11:12
Redeye comments on Annexin's Q1 report and recent events in the company. We have made a handful of adjustments to our model surrounding timelines, financing, IP, and FX, which have led to a downward revision of the valuation range. We believe Annexin is well-positioned to secure a licensing agreement, supported by the compelling phase IIa results. This update also provides a short case recap.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
11 juni, 11:12
Redeye comments on Annexin's Q1 report and recent events in the company. We have made a handful of adjustments to our model surrounding timelines, financing, IP, and FX, which have led to a downward revision of the valuation range. We believe Annexin is well-positioned to secure a licensing agreement, supported by the compelling phase IIa results. This update also provides a short case recap.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
Veckans analyser
Fortnox-budet
Veckans analyser
Fortnox-budet
1 DAG %
Senast
OMX Stockholm 30
1 DAG %
Senast
2 459,61